Maria Dall'Era

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide
    Maria Dall'Era
    University of California, San Francisco, 94143 0633, USA
    Arthritis Care Res (Hoboken) 63:351-7. 2011
  2. ncbi B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
    Stacey R Dillon
    Preclinical Research and Development, ZymoGenetics, Inc, 1201 Eastlake Ave East, Seattle, WA 98102, USA
    Arthritis Res Ther 12:R48. 2010
  3. ncbi Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial
    Maria Dall'Era
    Division of Rheumatology, University of California San Francisco 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Arthritis Rheum 56:4142-50. 2007
  4. ncbi Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies
    Maria Dall'Era
    University of California, San Francisco, USA
    Curr Rheumatol Rep 13:308-16. 2011
  5. ncbi Mycophenolate mofetil in the treatment of systemic lupus erythematosus
    Maria Dall'Era
    University of California, San Francisco, San Francisco, California 94143 0633, USA
    Curr Opin Rheumatol 23:454-8. 2011
  6. ncbi Biologic therapy for systemic lupus erythematosus
    Maria Dall'Era
    Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA
    Discov Med 9:20-3. 2010
  7. ncbi Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California San Francisco, CA 94143 0920, USA
    Arthritis Care Res (Hoboken) 63:1170-7. 2011
  8. ncbi A quality indicator set for systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA 94143 0920, USA
    Arthritis Rheum 61:370-7. 2009
  9. ncbi Systemic lupus erythematosus clinical trials-an interim analysis
    Maria Dall'Era
    Division of Rheumatology, University of California, San Francisco, CA 94121, USA
    Nat Rev Rheumatol 5:348-51. 2009

Collaborators

Detail Information

Publications9

  1. ncbi Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide
    Maria Dall'Era
    University of California, San Francisco, 94143 0633, USA
    Arthritis Care Res (Hoboken) 63:351-7. 2011
    ..To this end, we utilized data from the Aspreva Lupus Management Study to identify possible baseline and early predictors of renal response to mycophenolate mofetil (MMF) or intravenous (IV) cyclophosphamide (CYC)...
  2. ncbi B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin
    Stacey R Dillon
    Preclinical Research and Development, ZymoGenetics, Inc, 1201 Eastlake Ave East, Seattle, WA 98102, USA
    Arthritis Res Ther 12:R48. 2010
    ..They are overexpressed in a variety of autoimmune diseases and reportedly exist in vivo not only as homotrimers, but also as BLyS/APRIL heterotrimers...
  3. ncbi Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial
    Maria Dall'Era
    Division of Rheumatology, University of California San Francisco 533 Parnassus Avenue, San Francisco, CA 94143, USA
    Arthritis Rheum 56:4142-50. 2007
    ..Atacicept is a TACI-Ig fusion protein that inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand...
  4. ncbi Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies
    Maria Dall'Era
    University of California, San Francisco, USA
    Curr Rheumatol Rep 13:308-16. 2011
    ..This article provides a discussion of several novel biologic agents at different stages of development for the treatment of SLE, as well as an analysis of newer data on agents that have been used in the treatment of SLE for many years...
  5. ncbi Mycophenolate mofetil in the treatment of systemic lupus erythematosus
    Maria Dall'Era
    University of California, San Francisco, San Francisco, California 94143 0633, USA
    Curr Opin Rheumatol 23:454-8. 2011
    ..This review will discuss the key studies that have contributed to our understanding of the efficacy and safety of MMF in the treatment of SLE...
  6. ncbi Biologic therapy for systemic lupus erythematosus
    Maria Dall'Era
    Department of Medicine, University of California at San Francisco, San Francisco, California 94143, USA
    Discov Med 9:20-3. 2010
    ..This encouraging news follows several disappointments in trials of other biologic therapies and provides a timely moment to reflect on where we stand, what we have learned, and what may lie ahead...
  7. ncbi Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California San Francisco, CA 94143 0920, USA
    Arthritis Care Res (Hoboken) 63:1170-7. 2011
    ..In addition, we compared the BILD to another recently developed patient-reported measure, the Lupus Damage Index Questionnaire (LDIQ), which was designed as a written survey...
  8. ncbi A quality indicator set for systemic lupus erythematosus
    Jinoos Yazdany
    Rosalind Russell Medical Research Center for Arthritis, University of California, San Francisco, CA 94143 0920, USA
    Arthritis Rheum 61:370-7. 2009
    ..To systematically develop a quality indicator (QI) set for systemic lupus erythematosus (SLE)...
  9. ncbi Systemic lupus erythematosus clinical trials-an interim analysis
    Maria Dall'Era
    Division of Rheumatology, University of California, San Francisco, CA 94121, USA
    Nat Rev Rheumatol 5:348-51. 2009
    ..This article provides an analysis of the major clinical trials in SLE, and offers an interpretation of the results that could illuminate the path forward...